MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

SIMPLE SUMMARY: Donor lymphocyte infusions (DLIs) are immune cells of the donor. They can potentially directly target leukemic cells. Thus, DLIs can be given to acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT) in order to prevent or treat relapse. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Teich, Katrin, Stadler, Michael, Gabdoulline, Razif, Kandarp, Jyoti, Wienecke, Clara, Heida, Bennet, Klement, Piroska, Büttner, Konstantin, Venturini, Letizia, Wichmann, Martin, Puppe, Wolfram, Schultze-Florey, Christian, Koenecke, Christian, Beutel, Gernot, Eder, Matthias, Ganser, Arnold, Heuser, Michael, Thol, Felicitas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416875/
https://www.ncbi.nlm.nih.gov/pubmed/37568726
http://dx.doi.org/10.3390/cancers15153911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416875/
https://www.ncbi.nlm.nih.gov/pubmed/37568726
http://dx.doi.org/10.3390/cancers15153911

Ejemplares similares